Skip to main content
. 2023 Apr 18;142(3):221–229. doi: 10.1182/blood.2023019631

Table 1.

Sociodemographic and disease characteristics of patients with ALL, overall and by poverty status

Variable Entire cohort (n = 592) Not in extreme poverty (n = 519) In extreme poverty (n = 73) P value
Age at diagnosis in years
 Median (range) 5 (1-19) 5 (1-19) 5 (1-18) .9
 Mean (±standard deviation) 6.1 (4.4) 6.1 (4.4) 6.1 (4.5) .9
Age at study enrollment in years
 Median (range) 6 (2-21) 6 (6-21) 6 (2-20) .8
 Mean (±standard deviation) 7.6 (4.5) 7.6 (4.5) 7.8 (4.6) .7
Length of follow-up in years
 Median (range) 7.9 (0.1-13.0) 7.9 (0.1-13.0) 7.0 (0.4-10.6) .05
Sex, n (%)
 Male 405 (68.4) 354 (68.2) 51 (69.9) .8
Race/ethnicity, n (%)
 African-American or Black 108 (18.2) 90 (17.3) 18 (24.7) <.001
 Asian 85 (14.4) 77 (14.8) 8 (11.0)
 Hispanic 207 (35.0) 163 (31.4) 44 (60.3)
 Non-Hispanic White 192 (32.4) 189 (36.4) 3 (4.1)
Parental education, n (%)
 ≤HS 205 (34.6) 154 (29.6) 51 (69.8) <.001
Household structure
 Number of household members, median (range) 4 (2-12) 4 (2-12) 6 (4-12) <.001
 Total number of children <18 y old, median (range) 2 (1-10) 2 (1-10) 3 (1-6) <.001
ALL subtype, n (%)
 B-lymphoblastic leukemia 521 (88.0) 454 (87.4) 67 (91.7) .2
 T-lymphoblastic leukemia 63 (10.6) 58 (11.2) 5 (6.8) .3
NCI risk group, n (%)
 Standard risk 345 (58.2) 303 (58.3) 42 (57.5) .9
Cytogenetics, n (%)
 Favorable 227 (38.3) 203 (39.1) 24 (32.8) .6
 Neutral 298 (50.3) 260 (50.1) 38 (52.1)
 Unfavorable 30 (5.1) 25 (4.8) 5 (6.8)
6MP dose intensity
 Median (range) 0.88 (0.03-2.97) 0.88 (0.03-2.97) 0.89 (0.4-1.50) .2
MTXDI dose intensity
 Median (range) 0.88 (0.2-2.74) 0.88 (0.2-2.74) 0.9 (0.26-1.46) .3

Favorable cytogenetics included t(12;21); hyperdiploidy; trisomy 4 and 10; or trisomy 4, 10, and 17. Unfavorable cytogenetics included t(9;22), t(4;11), hypodiploidy, or extreme hypodiploidy. Neutral cytogenetics implied absence of favorable or unfavorable cytogenetics.

Data were missing for

ALL subtype (n = 8) and

cytogenetics (n = 37).